Table 7. Clinical characteristics, molecular screening test results and family history of patients fulfilling the Amsterdam II criteria.

ID	Age at CRC (years)	Gender	Tumour localisation	MSI status	BRAF	Methylation status	Molecular analyses conclusion	Tumour in relative (age at diagnosis in years)	Germline test result
1	48	M	Right colon	MSI-H	Wt	Neg	LS likely	Mo:CR(54); Si:EN(55)	PMS2
2	46	F	Right colon	MSI-H	Wt	Neg	LS likely	Mo:EN(48); MatGrandMo:Ur(56); Fa:Pro(70) Si:CER(51);	MSH2
3	74	F	Rectum	MSS	Wt	Neg	Likely non-LS	Da:EN(48);Si:EN(49); MatGrandFa:Abd(70)
4	75	F	Right colon	MSS	Wt	Neg	Likely non-LS	Mo:CR(46); Bro:CR(78);Si:Cr(79)
5	67	M	Right colon	MSS	Wt	Neg	Likely non-LS	Bro:CR(35);Fa:Cr(85); PatGrandPa:Cr(60); PatUn:Abd(∼70); PatUn:Abd (∼70); PatAu:Abd(∼70); PatAu:Abd(∼70)
6	59	M	Rectum	MSS	Wt	Neg	Likely non-LS	Bro:CR(29); Mo:EN(40); MatAu:CR(58);MatAu:CR(63) Fa:Pro(65); 11 MatAu/MatUn:Unkn
7	81	M	Right colon	MSS	Wt	Neg	Likely non-LS	Bro:CR(70); Pat Un:CR(53); Pat Un CR(27); Pat Un:CR(50); Fa: ‘Bile/gall bladder’ Mat Un;Lung(smoker)	—
8	72	M	Right and left colon (synch)	MSI-H	Wt	Neg	LS likely	Si: CR(58). Da: CR(38); Pat.Un CR(53); Pat.Un Abd(50)	Germline test MLH1, MSH2, MSH6, PMS2, negative

Abbreviations: Abd=abdomen; Au=aunt; Bro=brother; CR=colorectal; CRC=colorectal cancer; Da=daughter; EN=endometrium; Fa=father; GrandFa=grandfather; GrandMo=grandmother; Mat=maternal; methylation status=promotor methylation of MLH1; Mo=mother; MSI=microsatellite status; MSI-H=microsatellite high; MSS=microsatellite stable; neg=no methylation; Pat=paternal; pos=methylation found; Pro=prostate; Si=sister; So=son; Un=uncle; Unkn=unknown; Ur=ureter or cancer of the ureter/renal pelvis; UT CER=uterine cervix; wt=no BRAF mutation.

Molecular screening analyses conclusion: LS=if possible LS; non-LS=if likely sporadic CRC.

Lynch syndrome-associated tumours=colorectal, endometrium, cancer of the small bowel and ureter or renal pelvic cancer.